Bavarian Nordic, with a diverse vaccine portfolio and $340 million in contracts for 2025, offers growth potential for investors despite regulatory risks. See more.
Shares muted; Clinuvel prioritises business focus; Life360 CEO sells 1.2pc shares; Citi starts Cettire with ‘sell’, cuts Lovisa to ‘sell’; FleetPartners set for share-buyback. Follow updates here.